Type W Human Endogenous Retrovirus (HERV-W) Integrations and Their Mobilization by L1 Machinery: Contribution to the Human Transcriptome and Impact on the Host Physiopathology by Grandi, Nicole & Tramontano, Enzo
 Viruses 2016, 8, 162; doi:10.3390/v9070162 www.mdpi.com/journal/viruses 
Review 
Type W Human Endogenous Retrovirus (HERV-W) 
Integrations and Their Mobilization by L1 
Machinery: Contribution to the Human 
Transcriptome and Impact on the Host 
Physiopathology 
Nicole Grandi 1 and Enzo Tramontano 1,2,* 
1 Department of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di 
Monserrato SS554, 09042 Monserrato, Cagliari, Italy; nicole.grandi2@gmail.com; tramon@unica.it 
2 Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche (CNR), 09042 Monserrato, 
Cagliari, Italy; tramon@unica.it 
* Correspondence: tramon@unica.it; Tel.: +39-070-6754538 
Academic Editors: David J. Garfinkel and Katarzyna J. Purzycka 
Received: 16 March 2017; Accepted: 20 June 2017; Published: 27 June 2017 
Abstract: Human Endogenous Retroviruses (HERVs) are ancient infection relics constituting ~8% 
of our DNA. While HERVs’ genomic characterization is still ongoing, impressive amounts of data 
have been obtained regarding their general expression across tissues. Among HERVs, one of the 
most studied is the W group, which is the sole HERV group specifically mobilized by the long 
interspersed element-1 (LINE-1) machinery, providing a source of novel insertions by 
retrotransposition of HERV-W processed pseudogenes, and comprising a member encoding a 
functional envelope protein coopted for human placentation. The HERV-W group has been 
intensively investigated for its putative role in several diseases, such as cancer, inflammation, and 
autoimmunity. Despite major interest in the link between HERV-W expression and human 
pathogenesis, no conclusive correlation has been demonstrated so far. In general, (i) the absence of 
a proper identification of the specific HERV-W sequences expressed in a given condition, and (ii) 
the lack of studies attempting to connect the various observations in the same experimental 
conditions are the major problems preventing the definitive assessment of the HERV-W impact on 
human physiopathology. In this review, we summarize the current knowledge on the HERV-W 
group presence within the human genome and its expression in physiological tissues as well as in 
the main pathological contexts.  
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1. Introduction 
In the last 15 years, great efforts have been made to provide a complete assembled sequence of 
the human genome, progressively revealing an unexpected, highly repetitive composition. 
Transposable elements (TEs) account, in fact, for >50% of our genetic material, while protein-coding 
regions constitute only the ~2% [1]. TEs can be broadly divided in two general classes, based on 
whether DNA or RNA serves as the intermediate in the process of transposition. Human Endogenous 
Retroviruses (HERVs) belong to class-I TEs, also called retrotransposons, which are characterized by 
a RNA intermediate that is reverse-transcribed into a double stranded DNA (dsDNA). This dsDNA, 
commonly called a provirus, is competent for the subsequent integration into the host cell genome 
[2]. In addition to HERVs, which have 5′ and 3′ long terminal repeats (LTRs), retrotransposons also 
comprise elements devoid of LTRs and characterized by 3′ poly(A) repeats that are critical for their 
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retroposition, namely long and short interspersed nuclear elements (LINEs and SINEs, respectively) 
[3].  
HERVs are remnants of ancient retroviral infections acquired by the host genome in several 
waves that occurred mostly between 100 and 40 million years ago [4]. HERVs were once exogenous 
retroviruses and, in contrast to the retroviruses currently threatening humans, their infection not only 
affected somatic cells, but also involved, in particular, the germline. Hence, at the time, the proviral 
integration into the germline cells’ DNA made HERV sequences stable components of our genome 
(Figure 1). Such a process of endogenization and the further fixation in the human population have 
allowed HERVs to be vertically transmitted to offspring in a Mendelian fashion, constituting up to 
~8% of the human genome [1]. In general, HERV sequences have been formed by a traditional process 
of reverse transcription and integration, and thus show a classical proviral structure. The latter is 
characterized by an internal portion, including the main retroviral genes (gag, pro, pol, and env), 
flanked by the two LTRs. Owing to their long-time persistence in the host genome, however, 
individual HERV sequences have independently accumulated nucleotide substitutions, deletions, 
and insertions, often leading to the loss of coding capacity. In several cases, the homologous 
recombination between the two LTRs of a same provirus led to the elimination of the whole internal 
portion [5], a phenomenon reflected by the several thousands of solitary LTRs widespread in the 
human genome. 
Figure 1. Retrovirus endogenization and human endogenous retroviruses (HERV) formation. During 
replication, retroviral RNA is reverse-transcribed into a double stranded DNA (dsDNA) provirus and 
integrated into the cellular genome. All current human retroviruses target somatic cells, showing a 
horizontal transmission from an infected individual to new hosts. The exogenous retroviruses that 
gave rise to HERVs were also able to infect germ line cells. In this way, the integrated HERV sequences 
have been inherited in a Mendelian fashion, being vertically transmitted through the offspring and 
fixed into the human genome. During evolution, the majority of HERVs accumulated mutations that 
generally compromised their coding capacity. In several cases, the homologous long terminal repeat 
(LTR)-LTR recombination has led to the elimination of the whole internal portion, leaving only a 
solitary LTR as a relic. 
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Despite the abundant presence of HERVs in the human DNA, their general classification at the 
genomic level has been incomplete and sometimes controversial, due to the increasing amount of 
bioinformatics data and the concomitant absence of precise taxonomic rules [6]. Based on sequence 
similarity with respect to the exogenous retroviruses, HERVs were originally divided into three main 
classes: class I (Gammaretrovirus- and Epsilonretrovirus-like), class II (Betaretrovirus-like), and class III 
(Spumaretrovirus-like). Each class encloses a variable number of HERV groups, which have been 
named with discordant criteria in over the years, e.g., based on the human tRNA putatively 
recognized by the primer binding site (PBS) (e.g., HERV-K for Lysine, HERV-W for Tryptophan, and 
so on) or according to the name of a nearby gene (e.g., HERV-ADP) or a particular amino acid motif 
(e.g., HERV-FRD). Only very recently, the human genome assembly GRCh37/hg19 has been analyzed 
with RetroTector program (ReTe) [7], leading to the recognition and global characterization of >3000 
HERV insertions [8]. A multi-step classification approach, based on similarity image analysis, pol 
gene phylogeny and taxonomic feature identification, allowed characterization of 39 “canonical” well 
defined groups of HERVs, and 31 additional “non-canonical” clades [8]. Interestingly, HERV 
sequences included in the latter showed several degrees of mosaicism that mainly occurred as the 
consequence of recombination and secondary integration events [8]. Moreover, this comprehensive 
classification provided a reliable background for the exhaustive characterization of individual HERV 
groups at the genomic level, which still remains a major genetic and bioinformatics goal [9].  
In contrast to the genomic characterization, which is still ongoing for most of the HERV groups, 
there are many studies - mainly based on microarrays, hybridization assays or reverse transcriptase 
polymerase chain reaction (RT-PCR) approaches – that assessed HERV expression in healthy human 
tissues and cell lines [10–17]. These reports suggested that HERVs are stable components of the 
human transcriptome, and display differential expression among the diverse human tissues. In 
particular, variability of HERV transcription between healthy and pathological samples acted as a 
driving force to determine HERV’s role in several human disorders, such as cancer, inflammation, 
autoimmunity, and infectious diseases. Overall, even if the relevance of HERVs expression to the 
human physiopathological transcriptome is undeniable, its association with the diverse pathological 
conditions has lacked, until now, sufficient support. In fact, due to the absence of an unequivocal 
cause-effect relationship between HERV expression and any human disease [18–20], a number of 
studies unfortunately ended in the field of “rumor-virology” [18]. As mentioned above, the failure to 
establish cause–effect relationships primarily depends on the lack of proper characterization of the 
HERV single groups at the genomic level. The latter is essential to understand which precise HERV 
sequence is expressed in a given circumstance [21], and if its expression is beneficial, detrimental, or 
just functionally linked to a specific condition. It is also important to consider that many of the 
diseases tentatively linked to HERV expression are chronic conditions with a poorly understood 
etiology, in which several other factors (either genetic or environmental) could potentially produce a 
causal association [18]. All these aspects have to be considered in relation to the wide panorama of 
disparate HERVs expression studies, which includes many disparate data and very few studies 
attempting to assess the various observations in the proper standardized experimental conditions 
[18]. Thus, once it is established that HERV transcripts are stable signatures of many pathological 
conditions, the reliable assessment of their specificity and causality to various diseases will be 
required to explore HERVs as both etiological contributors and innovative therapeutic targets.  
Among HERVs, the HERV-W group is one of the most intensively investigated for its possible 
physiopathological effects on the host. After its initial identification as putative causative agent for 
multiple sclerosis (MS) [22], strong expression of the HERV-W group was found in placental tissues 
[23]. This observation led to the identification of a single HERV-W member (ERVWE1, locus 7q21.2) 
still able to encode a functional Envelope (Env) protein, which, during evolution, has been coopted 
for an important function in placentation [24,25]. On the one hand, this individual HERV-W element 
and its physiological role have been described in great detail [26–31]; on the other hand, the general 
expression of the HERV-W group has been broadly investigated in a variety of tissues, mainly to find 
correlations with human diseases. In this way, the HERV-W group hyperexpression has been 
reported in a great number of pathological contexts, making it one of the most promising endogenous 
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elements to be exploited for novel therapeutic and diagnostic strategies. However, in the great 
majority of cases, the observed expression profiles were yet not linked to any specific HERV-W 
sequence, preventing so far a definitive association with human pathology.  
It is noteworthy that in contrast to all other known HERV groups, HERV-W transcripts have the 
unique capacity to be mobilized by LINE-1 (L1) human retrotransposons [32,33]. HERV-W 
colonization of primate genomes was, in fact, mainly sustained by the L1-mediated formation of 
processed pseudogenes. This occurred through the reverse transcription of RNA transcripts 
originating from preexisting HERV-W proviral insertions, and their subsequent integration in new 
chromosomal positions [32,33] (see Figure 2 and paragraph 2). Considering that the human genome 
contains about 80–100 L1 elements still competent for retrotransposition [34–36], the expression of 
integrated HERV-W sequences could represent an indirect source of ongoing insertions. This would 
be more likely to happen in those pathological contexts characterized by an altered epigenetic 
environment, which could strongly liberate HERV expression, such as cancer and autoimmunity. In 
this way the general abundance of HERV-W transcripts reported in many tissues could provide a 
great number of RNA sequences suitable for L1 mobilization, possibly contributing to the intra- and 
inter-individual genetic variability and being responsible, occasionally, for sporadic insertional 
mutagenesis and genetic disorders [34–36]. 
The present review focuses on the HERV-W group as an example of the multifaceted effects that 
retrotransposon movement can exert on the host. In fact, although TEs have been considered as mere 
genomic parasites for a long time, the presence of such a wide proportion of mobile elements in 
eukaryotic DNA suggests that they cannot be only detrimental to the host [37]. Hence, we provide a 
comprehensive overview of the HERV-W group potential impact on human biology, summarizing 
its contribution to the human genome and the current knowledge of its expression in physiological 
conditions and, above all, in pathological contexts. We also briefly discuss the current needs for the 
definitive assessment of the HERV-W expression biological significance, and the future perspectives 
for its specific exploitation as innovative biomarkers and/or therapeutic targets for a wide range of 
human diseases.  
2. HERV-W Group Contribution to the Human Genome 
As for the other HERV groups, HERV-W integration in human germ line cells resulted from 
traditional retroviral infection (Figure 2). In general, it is still not clear whether the exogenous 
retrovirus progenitor of HERVs had germ line cells as their specific target or infected such population 
by chance [38]. In any case, after the entry into germ line cells, the viral RNA was reverse transcribed 
into proviral dsDNA, flanked by identical LTRs and competent for the insertion into the host cell 
genome. Repeated integration events determined the initial spread of HERV-W within human 
chromosomes, with new provirus formation possibly occurring even in the absence of an infectious 
phase [35] by intracellular reverse transcription and integration of the proviral RNA transcripts [38] 
(Figure 2). In addition, differently from all other known HERV groups, the HERV-W acquisition by 
primate genomes has been for the most part sustained by the L1-mediated formation of processed 
pseudogenes [32,33] (Figure 2). L1 elements encode for a protein with both reverse transcriptase and 
endonuclease activities [39]. Through these proteins, L1 sequences can copy and paste into new 
genomic positions not only their RNA, but also the transcripts generated by non-autonomous 
retrotransposons (Alu and SINE–VNTR–Alu, or SVA) and by HERV-W proviruses. According to this 
model, RNA transcripts originating from preexisting HERV-W proviral insertions were reverse 
transcribed and integrated into additional chromosomal loci by the L1 machinery. These HERV-W 
processed pseudogenes are characterized by specific signatures that structurally resemble viral 
mRNA: (i) truncated 5′ and 3′ LTRs, showing a R-U5 and U3-R structure instead of the traditional 
U3-R-U5 structure, respectively; (ii) a poly(A) tail of variable length, and (iii) a TT/AAAA insertion 
motif and a 5–15 nucleotides target site duplication [21,32]. As reported in the few studies aimed at 
characterizing the group at the genomic level [21,32,33], L1-mediated processed pseudogenes 
acquisition has not been a minor event in the HERV-W diffusion, having formed >2/3 of the group 
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members. The molecular model of L1-mediated HERV-W transcripts retrotransposition, as well as 
the specific determinants that limited the process to this HERV group, still remain to be clarified. 
 
Figure 2. HERV-W sequence amplification in germline cells. The initial acquisition of HERV-W 
sequences has been due to a traditional retroviral infection process. The viral RNA was reverse 
transcribed and the proviral dsDNA was integrated into the host cell genome by reverse transcriptase 
(RT) and integrase (IN) viral enzymes, respectively. Integrated provirus expression provided viral 
mRNAs, which generated new HERV-W insertions (red stars) through (i) L1-mediated 
retrotransposition: copy and paste mechanism in which viral mRNAs were reverse-transcribed by L1 
RT and inserted into a new genomic position, generating HERV-W processed pseudogenes; (ii) 
reinfection: proviral mRNAs were translated and the deriving proteins assembled into a mature viral 
particle, that after its egress could have re-infected the same cell; (iii) cis-retrotransposition: HERV-W 
mRNAs could have been used as templates for further reverse transcription–integration events, 
leading to the acquisition of new insertions in the absence of an extracellular phase. Owing to the 
accumulation of mutations over time, the last two mechanisms could have required proteins provided 
in trans by a helper virus. As shown in the table that reports the number of HERV-W insertions in 
each chromosome, the L1-mediated processed pseudogenes formation was responsible for the 
acquisition of about the 2/3 of the HERV-W sequences. 
Three independent studies performed a number of years ago on either isolated human 
chromosomes [40] or incomplete draft versions of the human genome characterized the HERV-W 
group at the genomic level [32,33]. Although these studies certainly represent milestones in the 
analysis of the HERV-W group, the use of different methodologies led to discordant results, currently 
difficult to retrieve and, especially, to correlate with modern expression data. Recently, a new 
bioinformatics analysis of the human genome assembly GRCh37/hg19 defined, for the first time, the 
precise localization and detailed description of 213 HERV-W insertions. The latter were classified, 
according to their general structure, into proviruses (65), L1-mobilized processed pseudogenes (135), 
and undefined sequences lacking both LTRs (13) [21]. In this study, the exhaustive characterization 
of each single HERV-W member in terms of estimated time of integration, genomic context of 
insertion, and nucleotide sequence provided a dataset that distinguishes the uniqueness of each 
HERV-W sequence. This dataset is particularly valuable for determining the link between the 
observed HERV-W expressed products (RNA and proteins) and their specific locus of origin [21]. In 
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addition, some insights regarding the HERV-W group taxonomy were reported for the first time, 
such as the presence of a second Gag nucleocapsid Zinc finger and the classification of the HERV-W 
members in two phylogenetic subgroups (named 1 and 2) based on both LTR phylogeny and key 
mutations [21]. Interestingly, even if the transcripts originated from both HERV-W subgroups were 
mobilized by the L1 machinery to generate processed pseudogenes, the mechanism was more 
frequent for subgroup 1 than for subgroup 2 proviruses (1:2.5 and 1:1 ratio, respectively) [21]. The 
reason for is unclear, but it is possible that the presence of specific sequences made the 
retrotransposition of subgroup 1 transcripts more efficient or, alternatively, that subgroup 2 elements 
were expressed at lower levels. Hence, the analysis of the single HERV-W insertions could provide 
information about L1-mediated HERV-W processed pseudogene formation, which is important for 
assessing novel retrotransposition events in disease contexts. The molecular elucidation of such 
events could be important to finally establish the possible pathogenic role of HERV-W processed 
pseudogenes that, due to their defective structure, have been often disregarded in expression studies, 
and are thus still poorly investigated in the human physiopathological environment. 
In the following sections, we summarize the current knowledge about the HERV-W group 
expression in both physiological and pathological tissues, based on the many studies performed in 
the past twenty years. With very few exceptions, these studies investigated the HERV-W group 
general expression, i.e., without any information on the transcripts genomic origin (specific HERV-
W locus) and the structure (provirus or processed pseudogene). If, on the one hand, the available 
data suggest that HERV-W sequences are differentially expressed in almost all analyzed tissues, 
being often hyperexpressed in the presence of diseases, on the other hand, these observations deserve 
more specific investigation aimed at finally identifying which HERV-W loci are selectively 
deregulated in various conditions.  
3. HERV-W Placental Expression and Syncytin-1 Env Protein Cooption for Human Physiology 
The reported presence of retroviral particles with reverse transcriptase (RT) activity in MS 
patients samples [41,42] led to the first description of the so called “MS Retrovirus” (MSRV). 
Subsequent Southern blot analysis using MSRV-derived probes allowed detection of a previously 
undescribed HERV multicopy family [22], formally named as HERV-W group [23]. Interestingly, the 
molecular characterization of the group coding capacity revealed a strong expression restricted to 
placenta [24] (apart from minor expression in testis [25]), showing the presence of a complete open 
reading frame (ORF) encoding for two major env transcripts (4 and 8 kb) [24,25]. Such ORF was shown 
to produce a 538 amino acids functional Env protein [23] that was mapped to a HERV-W locus on 
chromosome 7q21.2 (ERVWE1) [25]. ERVWE1 harbored a 5’LTR functional promoter, exhibiting 
several binding sites for transcriptional regulators involved in the control of proliferation and 
differentiation [26,43]. ERVWE1 Env protein was expressed in a panel of different species cell lines, 
interacting with the type D mammalian retrovirus receptor (hASCT2, human sodium-dependent 
neutral amino acid transporter type 2) strongly inducing syncytia formation [24,25]. It was therefore 
named Syncytin-1 [25]. The evidence that syncytia formation could be specifically impaired by 
Syncytin-1 inhibition (through both specific antibodies [24,25] and anti-sense transcripts [44]) 
confirmed a central role of this Env protein in the homo- and heterotypic fusogenicity [24,25]. Even 
if the cell-cell fusion mediated by Syncytin-1 primary depends on its interaction with hASCT2 
receptor [24], this Env can efficiently also bind to hASCT1 [45] and even the highly divergent mouse 
orthologous transporters, mASCT1 and mASCT2, after the elimination of their N-linked 
glycosylation sites [45]. This flexibility indicates a lower restriction of receptor usage as compared to 
the other retroviral Env proteins, probably due to the strong selective pressure acting on Syncytin-1 
throughout evolution [45]. Syncytin-1 placental expression has been specifically confirmed in the 
villous [25] and extravillous trophoblasts [46], and its strong fusogenic activity has been associated 
with the formation of the villous syncytiotrophoblast, the main site for trophic exchanges and other 
placental functions essential for fetal growth and development [24,25]. Beside its central fusogenic 
role, Syncytin-1 is also directly involved in cytotrophoblast differentiation and proliferation, which 
is essential for syncytiotrophoblast homeostasis [44,47]. In fact, Syncytin-1 siRNA knockdown in 
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BeWo cultures reduced cell growth and proliferation, probably through cell cycle arrest in G1 phase 
[47]. In contrast, ectopic overexpression of Syncytin-1 stimulated, as expected, trophoblast 
proliferation, confirming its critical role in promoting the G1/S transition during syncytiotrophoblast 
formation, and emphasizing a subtle balance of fusogenic and non-fusogenic functions in the co-
regulation of the cytotrophoblast pool [47]. Moreover, cyclic AMP (cAMP), known to regulate cAMP-
dependent protein kinases acting in trophoblast fusion and differentiation [48], is also able to control 
Syncytin-1 promoter [44]. The latter is a bipartite element formed by (i) the ERVWE1 5′LTR, which 
contains cAMP-responsive elements for placental basal expression, adjacent to (ii) a placenta-
restricted cellular enhancer, located within a MaLR (Mammalian apparent LTR retrotrasposon) 
solitary LTR and acting as URE (Upstream Regulatory Element), to confer high tissue-specific 
expression [29]. In addition to trophoblast cell-cycle regulation, Syncytin-1 seems to play a role also 
in the control of trophoblast survival, since the knockdown of its expression in BeWo cells triggered 
the death pathway mediated by apoptosis-inducing factor (AIF) [49]. 
In addition to the above mentioned functions in placental morphogenesis and homeostasis, 
Syncytin-1 was also hypothesized to have a role in maternal immunotolerance to the fetus [24,25,46] 
through its immunosuppressive domain [25], as previously shown for a murine [50] and a simian 
[51] retrovirus. Subsequent studies reported the absence of such activity in a mouse model, 
suggesting a genetic disjunction between fusogenic and immunosuppressive functions (at least in 
mice) [52]. In human blood, however, Syncytin-1 was effectively able to inhibit the production of Th1 
cytokines known to be important modulators of several immunological functions. This suggests a 
possible role of Syncytin-1 in mediating the shift from cytokine Th1 to Th2 observed during 
pregnancy that may also contribute to immunomodulation of the maternal system [53].  
4. General HERV-W Expression in Healthy Tissues Other than the Placenta 
The Syncytin-1 locus is exceptional, since it retains a residual protein-coding capacity, while the 
great majority of HERV sequences have accumulated mutations affecting protein production. For this 
reason, and due to their multi-copy nature, HERVs have often been disregarded in large-scale 
expression studies and, consequently, have not been exhaustively characterized in terms of functional 
significance [54]. A number of studies, however, investigated their expression across human tissues 
and cells. Overall, the results show that the various HERV groups display differential global 
expression profiles, which could be tissue/cell type-specific and vary depending on tissue state 
changes (e.g., differentiation, pathogenesis) as well as on environmental and individual conditions.  
As stated above, the HERV-W group is strongly expressed in normal placenta [23–25] and shows 
significant transcriptional activity in testis [25]. In addition, HERV-W transcription in healthy tissues 
has been monitored using RT-PCR protocols amplifying gag, pol or env genes with primers that, in 
general, were specifically designed for the placental Syncytin-1 ERVWE1 locus (Table 1). A few other 
studies investigated expressed sequence tags (ESTs) databases using Syncytin-1 proviral sequence as 
a query, or analyzed group expression using pol probes. In this way, general HERV-W expression has 
been detected in various human cell lines and healthy tissues—often lacking, however, any 
information about the transcript’s origin from specific loci (Table 1). 
Table 1. General type W human endogenous retroviruses (HERV-W) group expression in non-
placental healthy tissues. 
Tissue Method Ref. Possible Biases a 
Blood 
Search of Syncytin query in 
EST data  
[11] 
Low total HERV EST counts, could not detect HERV-Ws 
divergent from Syncytin, no information on LTR activity, 
number of cDNA/EST libraries great variability across 
tissues, under-representation of poorly expressed genes in 
small libraries (1) 
Brain 
Search of Syncytin query in 
EST data 
[11] (1) 
RT-PCR (gag+, pol+, env+) [55] 
Primers specific for single expressed sequences (placental 
Syncytin (gag: AF072500, env: AF072506), MSRV clones 
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(pol: AF009668)) could not detect divergent HERV-Ws, no 
information on full-length HERVs expression and LTR 
activity, samples amount is poorly representative (2) 
Brain (cortex 
and pons) 
env real time qRT-PCR [56] 
Primers specific for placental Syncytin (NM_014590.3) can 
could not detect env defective or highly divergent HERV-
Ws, no information on full-length HERVs expression and 
LTR activity, samples amount is poorly representative (3) 
Breast 
Search of Syncytin query in 
EST data 
[11] (1) 
env real time qRT-PCR [56] (3) 
Colon env real time qRT-PCR [56] (3) 
Heart RT-PCR (gag−, pol−, env+) [55] (2) 
Endometrium 
GammaHERV and HERV-
W pol-based probe and 
probe-less real time qPCRs 
[57] 
[14] 
Could not detect transcripts defective or highly divergent 
for pol gene, no information about full-length sequences 
expression and LTR activity, samples amount is poorly 
representative (4) 
Kidney 
pol-expression arrays 
hybridization 
[10] 
Cross-amplification/hybridization of related HERV groups; 
could not detect transcripts defective for pol gene, no 
information about full-length sequences expression and LTR 
activity, no quantitative information, samples amount is 
poorly representative (5) 
RT-PCR (gag−, pol+, env+) [55] (2) 
Liver 
pol-expression arrays 
hybridization 
[10] (5) 
RT-PCR (gag−, pol+, env+) [55] (2) 
env real time qRT-PCR [56] (3) 
Liver-spleen 
(fetal) 
Search of Syncytin query in 
EST data 
[11] (1) 
Lung RT-PCR (gag−, pol+, env+) [55] (2) 
Ovary 
Search of Syncytin query in 
EST data 
[11] (1) 
GammaHERV and HERV-
W pol-based probe and 
probe-less real time qPCRs 
[57] 
[14] 
(4) 
PBMC 
pol RT-PCR and env real 
time PCR [17] 
Low sensitivity and cross-amplification of related HERV 
groups by RT-PCR degenerate primers, real time PCR 
primers specific for placental Syncytin (NM_014590.3) could 
not detect divergent HERV-Ws and transcripts defective for 
pol/env genes, no information on full-length sequences 
expression and LTR activity, incomplete characterization of 
individuals health status 
Prostate RT-PCR (gag−, pol+, env+) [55] (2) 
Skel. Muscle RT-PCR (gag−, pol+, env+) [55] (2) 
Spleen RT-PCR (gag+, pol+, env+) [55] (2) 
Stomach env real time qRT-PCR [56] (3) 
Testis RT-PCR (gag+, pol+, env+) [55] (2) 
Thymus RT-PCR (gag−, pol+, env+) [55] (2) 
Uterus 
RT-PCR (gag−, pol−, env+) [55] (2) 
env real time qRT-PCR [56] (3) 
General HERV-W expression was reported by Stauffer et al. in the blood, brain, breast, liver/spleen, 
ovary and placenta, and subsequent analysis confirmed such results for placental and breast tissues 
only [11]. The physiological HERV-W env transcription in healthy brain and breast was detected also 
by Kim et al. [56]. Yi et al. investigated the HERV-W gag, pol and env genes expression within 12 tissues 
(brain, prostate, testis, heart, kidney, liver, lung, placenta, skeletal muscle, spleen, thymus, and 
uterus), detecting env transcripts in all the analyzed samples and reporting also some tissue-specific 
expression for gag and pol [55]. HERV-W RNA expression was also reported in the normal 
endometrium and ovary [14,57] and in the colon, liver, stomach, and uterus [56]. The HERV-W group 
was found to be transcriptionally active in peripheral blood mononuclear cells (PBMC) since early 
childhood [17]. High resolution melting temperature analysis [58] assessed the occurrence of 
systematic variations in the HERV-W gag sequences expression in primary fibroblasts, depending on 
both tissues and individuals considered [59]. a Methodological biases potentially affecting the 
effective and specific detection and characterization of the expressed HERV-W sequences. After the 
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first citation, biases with multiple citations are reported as a number into round brackets. EST: 
expressed sequence tags; LTR: long terminal repeats; MSRV: multiple sclerosis retrovirus; qRT-PCR: 
quantitative reverse transcriptase PCR; PBMC: peripheral blood mononuclear cells. 
In summary, global HERV-W transcriptional activity in healthy conditions was reported by at 
least one study in the brain, breast, skeletal muscle, spleen, lungs, digestive trait (stomach, liver, 
colon), genitourinary apparatus (ovary, endometrium, uterus, prostate, testis, and kidneys), and 
cardiovascular system (heart, whole blood, peripheral blood mononuclear cells (PBMC)). It is 
noteworthy that all these reports assessed the HERV-W group generic expression, i.e., without 
connecting the observed transcripts to a specific locus. Moreover, significant biases could derive from 
the use of Syncytin-1 provirus and/or MSRV cDNA clone sequences as a query and for the design of 
primers and probes. This could lead, in fact, to the lack of detection of HERV-W expressed loci with 
divergent nucleotide sequence as compared to the query, or defective for the single genes analyzed. 
Another possible bias is due to the potential contamination with genomic DNA, possibly 
representing a further complication in the analysis of multicopy repetitive elements, if not prevented 
through a correct treatment of RNA samples, e.g., with DNase. Finally, in the majority of cases, no 
information on the full-length HERV-W sequences expression and the LTR residual regulatory 
activity are available, and the samples are often limited in number and sometimes incompletely 
characterized for the individual’s health status.  
An attempt to connect HERV transcriptome to specific loci of origin was performed by Pérot et 
al. through a dedicated microarray designed on a collection of >5500 HERVs (including both 
proviruses and solitary LTRs) that could be reasonably allocated to unique genomic loci [15]  
(Table 2). Based on their results, the HERV-W group showed, as expected, predominant expression 
in placenta and testis, attributable to Syncytin-1 locus activity. In addition, five other specific HERV-
W loci (one provirus, one processed pseudogene, and three solitary LTRs) were also transcribed in 
the same tissues, showing in two cases a concomitant LTR promoter activity [15]. Despite the fact that 
the tissues considered by Pérot et al. were limited (colon, lung, breast, ovary, prostate, testis, uterus 
and placenta) and that all expressed HERVs are co-localized within human genes that could influence 
their transcription, the analysis is a remarkable effort to match HERV transcriptome to its specific 
genomic contributors, taking into account relevant aspects such as promoter activity and tissue 
specificity. 
Table 2. Specific HERV-W loci for which an expression in healthy tissues has been reported. 
Locus Chr:start-end (Strand) a Type Genomic Context b Tissue Method Ref. 
2q22.1 2:139030735-139031481 (−) Solo LTR LTR8 (+) Testis Microarray [15] 
2q24.3 2:165514421-165516121 (−) Pseudogene COBLL1 (−) 
TCONS_00004484 (−) Placenta Microarray [15] 
5q12.1 * 5:59954322-59962280 (+) Provirus DEPDC1B (−) Placenta Microarray [15] 
7q21.2 * 7:92097313:92107506 (−) Provirus - Placenta  Testis 
Northern 
blot 
[23] 
[25] 
15q21.2 15:51552784-51553570 (+) Solo LTR CYP19A1 (−) Placenta Microarray [15] 
Xq21.33 X:93824238-93824702 (−) Solo LTR MER4A (−) Placenta Microarray [15] 
a Chromosomal positions are referred to genome assembly GRCh37/hg19. The Syncytin locus is 
highlighted in bold. b Localization of HERV-W element within a human gene (italic names correspond 
to non-coding elements). For sequences marked with an * LTR promoter activity has been also 
reported.  
5. Syncytin-1 Expression in Placental Pathologies 
Consistent with its proven role in human placentation, Syncytin-1 abnormal expression has been 
observed in various pathological conditions affecting placental and maternal-fetal physiology, i.e., 
Pre-eclampsia (PE); hemolysis elevated liver enzymes and low platelet count (HELLP) syndrome; 
Trisomy 21; intrauterine growth restriction (IUGR) and endometriosis. The main findings in these 
pathological contexts are summarized below and in the Supplementary Materials (Table S1). 
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In general, it is worth noting that in many of the diseases affecting placental tissues, hypoxia is 
a common pathological trait able to influence Syncytin-1 expression (Table S1). In light of this, 
Syncytin-1 downregulation, commonly observed in diseased placentas, and the consequent reduction 
in trophoblasts fusion and differentiation, is likely to result from the pathological hypoxic 
environment.   
PE is a multisystem condition affecting ~5% of pregnant women [60]. It is clinically characterized 
by hypertension, proteinuria and hypoxia, and is associated with adverse perinatal outcome and 
preterm birth. A significant fusion reduction in trophoblast cells isolated from PE placentas was 
reported [61] and, in line with this, the placentas of women affected by PE showed a marked decrease 
in Syncytin-1 expression [61–65]. Such reduction seems to be correlated with PE severity [61] and 
depends on Syncytin-1 promoter hypermethylation [65], leading to a consequent decrease in 
cytotrophoblast differentiation [43].  
Similar Syncytin-1 expression reduction was found in HELLP syndrome [62,63]. Considering 
that experimental hypoxia reduces Syncytin-1 expression by 80% in BeWo cells in vitro and in 
isolated placental cotyledons ex vivo [66], it has been suggested that such reduction in Syncytin-1 
expression might arise due to the HELLP failure in trophoblasts arterial transformation and the 
consequent poor placental perfusion [67].  
Reduced Syncytin-1 expression was also observed in trophoblast cells from placentas bearing a 
trisomy 21 fetus. Trophoblast cells were still able to aggregate, but fused poorly or late in culture [68–
70], and showed increased levels of superoxide dismutase encoded on chromosome 21 [71]. When 
this antioxidant enzyme was overexpressed in normal cytotrophoblasts, impairment in 
syncytiotrophoblast formation as well as abnormal cell fusion and Syncytin-1 downregulation were 
observed, further suggesting that oxidative states are able to influence trophoblasts Syncytin-1 
production [68,71]. Since it is known that hypoxia can activate the caspase apoptotic pathway, the 
hypoxic environments common to many placental diseases could possibly lead to trophoblast cell 
death via both this mechanism and the above mentioned AIF pathway [47], specifically triggered by 
Syncytin-1 decreased expression [47,60].  
IUGR is another important cause of perinatal morbidity and mortality for both mother and fetus, 
and it is also related to hypoxia and abnormal trophoblast development. In line with this, IUGR 
placentas showed significantly lower Syncytin-1 RNA and protein amounts with respect to control 
placentas [64,72], although still sufficient to mediate trophoblast cells fusion [72].  
Finally, two studies reported a high HERV-W expression in endometriotic tissues, even though 
no great differences were found with respect to control tissues [14,57]. This Syncytin-1 upregulation, 
dependent on the hypomethylation of its promoter, has been proposed to be involved in 
endometriotic lesion development [73].  
Overall, these findings have confirmed a pivotal role of Syncytin-1 expression in placental 
physiology, and showed how its deregulation could contribute to maternal systemic disorders [60]. 
6. HERV-W Expression in Tumorigenesis and Cancer Progression 
Tumorigenesis is a complex multistep process involving both inherited and environmental 
factors and possible association with HERV expression. Of course, this link has been greatly sustained 
by the well-described transforming nature of exogenous animal retroviruses, which were originally 
designated as “RNA tumor viruses”. However, the high copy number and repetitive nature of 
HERVs may also trigger additional tumorigenesis mechanisms that do not require the production of 
infectious viral particles, as summarized in Figure 3. In particular, HERV mobilization and 
integration could be responsible for insertional mutagenesis events (panel a), which could disrupt or 
deregulate host genes (e.g., oncosuppressors, transcriptional regulators). The presence of repetitive 
elements could also trigger chromosomal rearrangements by non-allelic homologous recombination 
(panel b). HERV transcriptional de-repression, possibly prompted by the altered epigenetic 
environment commonly associated with cancerous tissues, can lead to uncontrolled activation of 
downstream cellular genes (e.g., oncogenes, transcription factors) (panel c). Even in the absence of 
protein production, HERVs transcription could stimulate the accumulation of incomplete replication 
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intermediates, which can activate innate immunity pathways and deregulate non-coding RNA 
networks (panel d). Finally, if a HERV protein is produced, its activities (e.g., fusogenic and/or 
immunosuppressive functions) and/or abilities (e.g., interaction with cellular proteins) may 
contribute to tumor development (panel e). 
 
Figure 3. Potential mechanisms of HERV-mediated transformation in tumorigenesis. (a) Insertional 
mutagenesis could disrupt/deregulate host genes; (b) non-allelic homologous recombination could 
induce chromosomal rearrangements; (c) transcriptional silencing abrogation could trigger LTR 
promoter activity; (d) accumulation of replication intermediates could evoke immunity and/or 
deregulate RNA networking; (e) protein production could evoke immunity and/or provide oncogenic 
functions. 
Remarkably, despite several studies that reported the general increase—or even the de novo 
appearance—of HERV-W transcripts in tumors as compared to healthy tissues (Table 3), it is yet to 
be understood whether such HERV overexpression is the cause or just a consequence of 
transformation. In fact, HERV expression is generally silenced by epigenetic mechanisms in normal 
cells, yet abnormal hypomethylation of CpG dinucleotides is commonly observed in tumor cells. This 
dysregulation could possibly lead to increased levels of HERV expression as an indirect product of 
the altered epigenetic environment, instead of a main determinant of the disease onset. 
Unfortunately, despite the central role of epigenetic changes in influencing HERV transcription, very 
few studies to date have analyzed the HERV-W sequences methylation status in tumor tissues. One 
study investigating the epigenetic state of L1 and HERV-W sequences in human ovarian carcinomas 
reported a consistent reduction in promoter methylation, corresponding to an increase in expression 
[74]. Upregulation of L1 and HERV-W expression could contribute to tumor progression by de novo 
mobilization of the abundant HERV-W transcripts. Interestingly, despite an overall increase in 
hypomethylation, some L1 and HERV-W sequences remained hypermethlyated in malignant 
samples [74]. This result raises the possibility of more specific regulation of HERV expression leading 
to a beneficial or detrimental effect on disease progression. HERV-W transcriptional increase in 
ovarian carcinomas has been reported by Hu et al., but a similar expression level was similarly 
observed in healthy ovaries, and the number of samples was too low to be statistically significant 
[57]. HERV-W expression has also been investigated in endometrial carcinomas, due to the presence 
of giant syncytial cells possibly mediated by Env fusogenic activity. Results showed that Syncytin-1 
was upregulated in both benign and malignant tissues; however, the highest expression was detected 
in endometrial carcinomas [75].  
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Table 3. General HERV-W group expression in tumoral tissues. 
Tumoral 
Tissue 
Ref. Method a 
Physiol.
Expression b 
Possible Biases of HERV-W Members 
Underrepresentation c 
B cells [55] * RT-PCR (gag−, pol−, env+) [17]° 
Primers specific for single expressed 
sequences (placental Syncytin-1 gag 
AF072500 and env AF072506; MSRV clones 
pol AF009668) could not detect divergent 
HERV-Ws, no information on full-length 
HERVs expression and LTR activity, samples 
amount is poorly representative (2) 
Bladder [55] * RT-PCR (gag−, pol+, env+) - (2) 
Breast 
[11] 
Search of Syncytin-1 in 
EST data 
[11,56] 
Low total HERV EST counts, could not detect 
HERV-Ws divergent from Syncytin-1, no 
information on LTR activity, number of 
cDNA/EST libraries great variability across 
tissues, under-representation of poorly 
expressed genes in small libraries (1) 
[76] * 
RT-PCR, real time qRT-
PCR, 
Specific detection of a Syncytin-1 env portion 
only, could not detect transcripts 
divergent/defective for env, no information 
on full-length sequences expression and LTR 
activity 
[56] env real time qRT-PCR 
Primers specific for placental Syncytin-1 
(NM_014590.3) could not detect env defective 
or highly divergent HERV-Ws, no 
information on full-length HERVs expression 
and LTR activity, samples amount is poorly 
representative (3) 
[55] * RT-PCR (gag−, pol+, env+) (2) 
Brain [55] * RT-PCR (gag−, pol+, env+) [11,55] (2) 
Colon 
[11] 
Search of Syncytin-1 in 
EST data 
[56] 
(1) 
[56] env real time qRT-PCR (3) 
[55] * RT-PCR (gag−, pol+, env+) (2) 
[77] * qPCR 
Specific detection of a Syncytin-1 env portion 
only, could not detect transcripts 
divergent/defective for env, no information 
on full-length sequences expression and LTR 
activity 
Endometrium [75] qPCR, RT-PCR, NB, WB [14,57,75] 
Specific detection of a small portion of 
Syncytin-1 env only, samples amount is 
poorly representative, expression values are 
highly heterogeneous 
Esophagus [55] * RT-PCR (gag−, pol+, env+) - (2) 
Histiocyte [55] * RT-PCR (gag−, pol+, env+) - (2) 
Kidney 
[11] 
Search of Syncytin-1 in 
EST data [10,55] 
(1) 
[55] * RT-PCR (gag−, pol+, env+) (2) 
Liver 
[56] env real time qRT-PCR 
[10,55,56] 
(3) 
[55] * RT-PCR (gag−, pol+, env+) (2) 
Lung [55] * RT-PCR (gag−, pol+, env+) [55] (2) 
Neuroblasts [78] * pol real time qPCRs - 
Could not detect transcripts defective or 
highly divergent for pol gene, no information 
about full-length sequences expression and 
LTR activity, samples amount is poorly 
representative (4) 
Ovary 
[74] Real time qRT-PCR 
[57,74] 
Primers designed on Syncytin-1 locus 
(AC000064) could not detect divergent 
HERV-Ws, samples amount is poorly 
representative 
[57] pol real time qPCRs (4) 
[55] * RT-PCR (gag−, pol+, env+) (2) 
Pancreas [55] * RT-PCR (gag−, pol+, env+) - (2) 
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Placenta [11] 
Search of Syncytin-1 in 
EST data 
[23–25] (1) 
Prostate [55] * RT-PCR (gag−, pol−, env+) [55] (2) 
Skin [55] * RT-PCR (gag−, pol−, env+) - (2) 
Stomach 
[56] env real time qRT-PCR 
[56] 
(3) 
[55] * RT-PCR (gag−, pol+, env+) (2) 
T-cells [55] * RT-PCR (gag−, pol+, env+) [17] ° (2) 
Uterus 
[56] env real time qRT-PCR 
[55,56] 
(3) 
[55] * RT-PCR (gag−, pol+, env+) (2) 
a NB = Northern Blot, WB = Western Blot; b Studies that reported the general group expression in 
healthy tissues; c Methodological biases that potentially affected the effective and specific detection 
and characterization of the expressed HERV-W sequences. After the first mention, biases with 
multiple citations are reported as a number; ° data obtained in total PBMC; * data obtained in cancer 
cell lines. 
In contrast to the above mentioned studies that reported an increase of HERV-W expression in 
tumor tissues, other studies reported no significant upregulation of HERV-W transcriptional activity 
in human cancers. Stauffer et al. investigated HERV-W expression in placenta, breast, colon, and 
kidney cancers, observing that the HERV-W transcription levels in healthy breast and placenta were 
higher than in corresponding tumor samples [11]. Similarly, Kim et al. reported no significant 
differences in HERV-W expression between paired tumor and normal adjacent tissues from breast, 
colon, liver, stomach, and uterus [56]. 
In addition to the analyses performed on tumor samples from patients, a number of studies 
investigated the HERV-W group transcriptional activity in cancer cell lines. These studies, however, 
could not reliably measure the HERV-W expression in cancers, showing a lack of correlation between 
the expression levels observed in normal tissues and the corresponding cancer cell lines [55]. 
Moreover, the observed upregulation of HERV-W expression could be, at least in part, a consequence 
of the tumor cell line environment instead of a specific signature of cancer. For instance, HERV-W 
RNA levels were increased in three neuroblastoma cell lines (SH-SY5Y, SK-N-DZ, and SK-N-AS), 
with a selective upregulation during hypoxia recovery and after the treatment with demethylating 
agents. Both treatments are known to influence HERV transcription with no specificity for tumor 
environment [78]. Similarly, Díaz-Caballo et al. reported a HERV-W hyperexpression in HCT8 colon 
carcinoma cells, and proposed a correlation with the induction of a chemotherapy-refractory state 
[77]. Such increased transcription, however, is possibly the consequence of the experimental 
induction of a cytostatic stress.  
Studies performed in additional cancer cell lines reported more specific effects associated with 
HERV-W hyperexpression. SH-SY5Y and another neuroblastoma cell line transfected with HERV-W 
env resulted in increased expression of SK3 (small conductance Ca2+-activated K+ channel protein 3), 
an ion channel relevant for neuronal excitotoxicity and linked to various diseases of the nervous 
system [79]. Such upregulation was proposed to depend on the activation of the SK3 promoter cAMP 
responsive elements (CRE) as direct consequence of the HERV-W Env-mediated increased 
phosphorylation of the activating transcription factor CREB (CRE-binding protein) [79]. Similarly, 
Bjerrgarden et al. hypothesized a direct role of Syncytin-1 fusogenic activity in breast cancer based 
on the fact that MCF-7 and MDA-MB-231 cells express Syncytin-1 on the cell surface and hence are 
able to fuse with endothelial cells presenting hASCT-2 receptor [76]. 
As previously described for HERV-W physiological expression, many reports assessed the 
altered HERV-W transcription in different tumor tissues, however, very few studies attempted to 
connect transcription to specific HERV-W loci (Table 4). These studies, even if not conclusive for the 
definitive association of HERV-W expression to tumor development, provide a more reliable picture 
of the single HERV-W elements upregulated in different human cancers, and suggest further 
investigations are warranted to determine HERV-W’s epigenetic status and specific roles in 
pathogenesis. Moreover, the identification of specific HERV-W loci expressed in cancer tissues also 
allows evaluation of their structural characteristics. It is interesting to note that, besides 9 HERV-W 
proviruses, a number of L1-generated processed pseudogenes (6) and solitary LTRs (8) are 
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specifically upregulated in cancer tissues (Table 4). This suggests that highly defective HERV-W 
elements, especially in the presence of an altered epigenetic control, can be actively transcribed and 
differentially expressed in cancerous tissues, possibly contributing to the disease progression.  
Table 4. Specific HERV-W loci reported as hyperexpressed in tumoral tissues. 
Locus Chr:start-end (Strand) a Type b Genomic Context c Tissue d LTR e Method f Ref. 
1q31.2 1:192855545-192856320 (−) LTR MER21C (−) Testis - MA [15] 
2p24.2 2:17520208-17527981 (+) PV L3 (−) Testis Pro ° MA, qRT-PCR [15,80] 
2p12 2:76098816-76106624 (+) PV - Testis Pro MA [15] 
3p12.3 3:74921984-74927237 (−) PG - Prostate - MA [15] 
3q28 3:191376573-191383381 (+) PG - Testis - MA [15] 
4p13 4:42287455-42294913 (−) PV TCONS_00007753 (−) Testis Pro ° MA, qRT-PCR [15,80] 
4q26 4:114965536-114972972 (+) PG - Testis - MA [15] 
5p13.3 5:31109366-31109859 (−) LTR - Ovary - MA [15] 
6q21 6:106676012-106683689 (+) PG ATG5 (−) Skin T cells - MA, qRT-PCR [81] 
7q21.2 7:92097313:92107506 (−) PV - 
Testis*  Pro ° MA, qRT-PCR [80] 
Bladder Pro qRT-PCR [82] 
Skin T cells - MA, qRT-PCR [81] 
7q21.3 7:95987661-95988433 (−) LTR Alu Sx (−) Testis - MA [15] 
7q31.1b 7:114019143-114026368 (−) PG FOXP2 (+) Testis - MA [15] 
7q36.3 7:155177752-155178503 (−) LTR BC150495 (+) Testis PA MA [15] 
8q24.13 8:125912007-125919468 (−) PV - Prostate Pro MA [15] 
13q21.1 13:55627766-55635877 (+) PV - Testis - MA [15] 
13q21.33 13:69795752-69799468 (+) PV LINC00383 (+) (Ex) Testis Pro ° MA, qRT-PCR [80] 
16p12.3 16:18124951-18125494 (−) LTR - Testis - MA [15] 
17q22 17:53088886-53095859 (−) PG STXBP4 (+) Testis - MA [15] 
21q21.1 21:20125060-20132866 (−) PV MIR548XHG (−) (Ex) Testis - MA [15] 
21q21.3 21:28226756-28234297 (+) PV - Testis Pro ° MA, qRT-PCR [15,80] 
Xq21.1 X:82517449-82517774 (−) LTR L1 PA11 (+), L1 MA2 (+) Testis - MA [15] 
Xq23 X:113140352-113141135 (−) LTR L1 (−), XACT (−) Testis Pro ° MA, qRT-PCR [80] 
Xq24 X:120490096-120490859 (+) LTR - Testis PA MA [15] 
a Chromosomal positions are referred to genome assembly GRCh37/hg19. Syncytin locus is 
highlighted in bold; b PV: provirus; PG: processed pseudogene, LTR: solitary LTR; c Elements co-
localized with HERV-W loci: italics indicates coding genes, (Ex) indicates HERVs within an exon; d 
Tissues for which the HERV-W sequence expression was reported also in physiological conditions 
are marked with *; e Reported activity of the sequences LTRs: Pro: promoter; PA: PolyA signal. The 
mark ° indicates a hypomethylated status with respect to normal samples; f MA: microarray. 
In particular, the majority of studies reported HERV-W sequence specific expression both in 
tumoral testis, along with the previously reported Syncytin-1 expression [25], and in a number of 
other cancers mostly affecting the genitourinary trait. Pérot and coworkers have analyzed paired 
normal and tumoral tissues through a dedicated microarray (see also paragraph 4 and Table 2), and 
reported a number of HERV-W loci that were differentially expressed in testis (16), prostate (2) and 
ovary (1) cancer samples [15]. Similarly, Gimenez and coworkers identified six HERV-W loci, 
including Syncytin-1, whose expression was upregulated in testicular cancer [80]. The precise 
localization of these expressed HERV-W sequences allowed comparison of their epigenetic status in 
normal and tumoral tissues, revealing, in the latter a U3 promoters hypomethylation in at least five 
out of the six loci [80]. As is the case for ovarian cancer [74], some sequences remained unmethylated 
in the tumor environments but not in the normal counterparts [80], suggesting the presence of 
different levels of HERV transcriptional control. When considering bladder urothelial cell 
carcinomas, Syncytin-1 was significantly hyperexpressed in >75% of the analyzed tumor tissues (n = 
82) as compared to the 6% of the matched adjacent tissues, increasing proliferation and viability of 
human immortalized uroepithelial cells [82]. In this case, the identification of specific HERV-W 
sequences significantly upregulated in tumor tissues also allowed detection of single nucleotide 
substitutions. The latter were found in positions 142 and 277 of the Syncytin-1 3′LTR, in ~88% tumoral 
tissues while they were observed only in a small proportion (~5%) of healthy controls. Interestingly, 
the T142C mutation apparently resulted in selective binding of the c-Myb transcription factor to 
ERVWE1 LTR, and was possibly associated with the selective enhancement of Syncytin-1 promoter 
activity in bladder urothelial cell carcinoma [82]. In addition, the expression of specific HERV-W loci 
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has been assessed in mycosis fungoides, the most common Cutaneous T-Cell Lymphoma (CTCL) 
[81]. In fact, two HERV-W loci in chromosomes 6 (6q21) and 7 (7q21.2—Sincytin-1), which frequently 
harbor abnormalities and rearrangements in CTCL, were predominantly and significantly 
upregulated in mycosis fungoides lesions as compared to the same patient intact skin [81]. 
Despite the number of studies investigating HERV-W expression (either general or associated 
with specific loci), no human cancer has been unequivocally related to this or any other HERV group. 
This greatly depends on the lack of definitive evidence that specific HERV sequences are effectively 
able to induce tumors through the so far proposed mechanisms. Although HERV expression in 
tumors may contribute to the disease’s clinical outcome, the currently available results suggest only 
that the HERV-W group has variable expression profiles in both normal and cancerous tissues [11]. 
As in previous cases, the use of different experimental approaches often affected by potential 
methodological biases, together with the lack of connection between the observed transcripts and the 
specific originating locus, currently impedes effective assessment of the biological significance of the 
HERV-W group expression in tumors. Moreover, the current lack of exhaustive information on 
HERV-W loci basal expression in healthy tissues clearly limits complete evaluation of their effective 
dysregulation in the corresponding tumors, which are further complicated by an altered epigenetic 
regulation. In light of this, even with clear evidence of differential HERV-W expression between 
tumoral and healthy tissues, further studies are needed to establish which HERV-W loci are actively 
involved in tumorigenesis and which ones constitute an “epiphenomenon” due to the altered tumoral 
environment [83]. 
7. HERV-W Expression in MS and Other Autoimmune Diseases 
Autoimmune diseases comprise a heterogeneous group of complex multifactorial disorders, all 
sharing the incorrect recognition of healthy cells and/or the loss of immune tolerance to self-Antigens 
(Ags) by the immune system. Clinically, such loss of tolerance leads to Antibody (Abs) production 
and/or cytotoxic T cells responses against body components, resulting in chronic inflammation and 
tissue destruction. A role for HERV in autoimmune disorders was primarily suggested by (i) the 
presence of retroviral Ags and/or specific Abs at the site of disease and in patients’ sera, respectively 
[84,85], and (ii) an increased HERV expression in patients with autoimmune disorders as compared 
to healthy individuals [86]. Theoretically, given that HERVs are stable components of the human 
genome, the immune tolerance to them should have been established during development. Despite 
this, HERVs still show the ability to induce, or at least to influence, both innate and adaptive 
immunity [84–89] (Figure 4). Currently, the most accepted theory is that HERV expression can evoke 
autoimmunity by molecular mimicry between common auto-Ags and exogenous retroviral proteins 
[86,90–93]. HERV RNAs and proteins may, in fact, be recognized as PAMPs (Pathogen Associated 
Molecular Patterns) by innate immunity pathogen recognition receptors (PRRs) (recently reviewed 
in [89]), that determine inflammation and auto-Ab production. Moreover, HERV proteins may act as 
super-Ags, triggering the non-specific polyclonal activation of auto-reactive T lymphocytes and 
inducing massive cytokine release. Besides the direct immunogenic effects of retroviral products, 
HERV proteins may affect the host immune response in additional ways, such as by trans-
activating/suppressing genes involved in immune modulation. Even in the absence of any expressed 
product, the mere presence of HERVs can contribute to autoimmunity through insertional 
mutagenesis events and/or cis-regulation of adjacent immune regulatory gene expression at the 
transcriptional and post-transcriptional level.  
Importantly, as described for cancer, autoimmunity is also influenced by abnormal 
hypomethylation, which can eventually release HERVs expression [94]. Such an occurrence, even as 
the mere consequence of epigenetic alterations, could contribute to immunopathogenesis by 
providing nucleic acids or proteins acting as PAMPs. Furthermore, the loss of epigenetic control can 
provide HERV-W transcripts suitable for de novo mobilization by L1. Therefore, the proper 
identification and characterization of the expressed HERV loci is essential to assess their effective 
involvement in the disease onset and progression. 
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Focusing now on the HERV-W group, the major field of investigation in autoimmunity is 
certainly MS, although few studies have been reported for other autoimmune or immune-related 
disorders.  
 
Figure 4. Potential mechanisms of HERV contribution to autoimmunity. HERVs can trigger 
autoimmunity through the direct sensing of their expression products by pathogen recognition 
receptors (PRRs) (red) as well as by mediating the deregulation of the host immune effectors and 
modulators (green). In both cases, the eventual hypomethylated status associated with autoimmunity 
can upregulate HERVs that are normally silenced in healthy tissues. HERV expressed RNAs and 
proteins (upper part) can act as pathogen associated molecular patterns (PAMPs) prompting the 
innate immunity effectors, and, consequently, evoking an adaptive response. HERV proteins can 
either act as super antigens Ags activating a polyclonal expansion of autoreactive T cells, or deregulate 
immunity genes. These mechanisms can be also based on the molecular mimicry of HERVs products, 
due to their identity with the exogenous elements. HERV integrated sequences, or even their sole 
LTR, (lower part) can affect the host immunity even in the absence of any expressed product, if their 
insertion disrupts or deregulates genes involved in immune response and its control.  
7.1. Multiple Sclerosis 
MS is an autoimmune disorder with poorly understood etiology, and characterized by 
progressive demyelination of the central nervous system (CNS). Both innate and adaptive immunity 
dysregulation contributes to MS immunopathogenesis, although adaptive immunity may 
predominate in the disease onset with selective T and B cell activation accompanying clinical relapses 
[95]. The precise causes of axon demyelination and damage remain unclear, even if inflammatory 
molecules such as cytokines, chemokines, prostaglandins, reactive oxygen species and matrix 
metalloproteinases contribute to MS [95]. In addition, different infectious agents have been 
investigated for a possible association with MS [95–101]. 
As previously mentioned, the HERV-W group was initially related to MS due to its nucleotide 
identity with MSRV [102,103], a putative retroviral element detected in some MS patients 
[22,41,42,104,105], and proposed as an exogenous competent member of the HERV-W group [22,106–
110]. The origin of MSRV is, however, still highly debated [18,111,112], and recent findings suggest 
that the previously identified MSRV sequences could have arisen from the expression of a single 
HERV-W locus, or the in vitro recombination of many HERV-W transcripts [21,113]. In the last twenty 
years, many studies investigated the HERV-W/MSRV involvement in MS, mainly by (i) the detection 
of HERV-W/MSRV nucleic acids in MS samples; (ii) the presence of HERV-W/MSRV Ags in MS 
lesions; (iii) the onset of an immune response against these elements, and (iv) the use of some animal 
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models of MS. Even if all these types of investigation are taken into account, the evidence strongly 
suggests that the presence of HERV-W/MSRV sequences (i) and Ags (ii) could contribute to a higher 
prevalence in MS. The clear immunopathogenic potential of these HERV products on cellular-
mediated immunity, as shown in both humans (iii) and animal models (iv), could indeed take part, 
together with other individual factors, to cause MS disease. 
7.1.1. Detection of HERV-W/MSRV Nucleic Acids in MS Samples 
Regarding the presence of HERV-W/MSRV nucleic acids, most studies focused on the detection 
of expressed HERV-W/MSRV RNA transcripts, while a few of them investigated the differential 
amounts of integrated DNA sequences copy-number in MS samples. 
HERV-W/MSRV pol RNA sequences have been detected by RT-PCR approaches in MS patient 
brain [114], leptomeningeal, choroid plexus and B cells [22], peripheral blood lymphocytes [115], 
cerebrospinal fluid (CSF) [22,115,116], serum [116,117] and plasma [115]. Overall, HERV-W/MSRV 
pol amplicons were found in a variable proportion of the MS samples (~50 to 100%) as well as in some 
healthy controls (0–50%) and non-MS pathological samples (0–65%). These results suggest that 
HERV-W expression may be associated with the pathological environment and have a role in a 
particular subset of susceptible individuals. Unfortunately, the expressed RNA sequences were not 
attributable to specific HERV-W loci [97]. Also MRSV/HERV-W env RNA expression was reported to 
be upregulated in MS patient brains [118,119] and PBMC [120]. Finally, a significantly higher 
accumulation of both HERV-W/MSRV pol and env RNAs was reported in MS brains [107] and CSF 
[121] with respect to healthy and pathological controls, even if all samples tested contained the 
HERV-W/MSRV transcripts regardless of health/disease status.  
HERV-W/MSRV DNA copy-number was reported to increase in PBMCs of MS patients as 
compared to controls, and copy number also correlated with disease severity [110,120]. Considering 
that active HERV-W proliferation ended several millions of years ago, before the evolutionarily 
speciation of humans [21], it is unlikely that such variation could depend on the presence of unfixed 
proviral integrations in the modern population, as shown for younger HERV groups. It is indeed 
more probable that, as described above, the additional HERV-W copies found in MS patients could 
be due to processed pseudogenes derived from novel L1-mediated retrotransposition events 
triggered by the autoimmune hypomethylated environment. A positive relationship between HERV-
W/MSRV DNA copy number and female gender has been also hypothesized, which is consistent with 
the higher incidence of MS in women. In particular, the one proviral copy and 10 L1-generated 
processed pseudogenes of HERV-W on the X chromosome could possibly play a role in MS sex-based 
variants, similarly to other X chromosome abnormalities [110]. Finally, MSRV pol sequences have 
been detected by fluorescence in situ hybridization (FISH) in the peripheral blood cell DNA from all 
patients with active MS and healthy controls tested, which supports an endogenous origin of MSRV 
[116,122].  
7.1.2. Presence of HERV-W/MSRV Ags in MS Lesions 
As is the case for HERV-W/MSRV nucleic acids, the presence of HERV-W/MSRV proteins has 
been reported in both normal and MS brain tissues, thus questioning their direct role in MS 
pathogenesis. However, the presence of HERV-W/MSRV proteins in diseased sites suggests that they 
may contribute to MS immunopathogenicity and clinical manifestations. In fact, Syncytin-1 protein 
was present in MS patient brains and in specific cell types involved in lesions, neuroinflammation, 
and were expressed at a low level [118] or absent [107,120] in controls. In addition, Syncytin-1 in vitro 
expression mediated the production of proinflammatory molecules, potentially involved in 
astrocytes and oligodendrocyte damage [95], and an accumulation of HERV-W Gag Ags was shown 
in MS demyelinated brain lesions [123]. Also, HERV-W Env epitopes were detected in higher 
quantities on the surface of B cells and monocytes from patients with active MS with respect to stable 
MS patients and healthy controls [124]. Finally, HERV-W/MSRV Env protein abundance in MS brain 
lesions was recently associated with areas of active demyelination, being predominantly expressed 
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by macrophages and microglia, while moderate expression was observed in reactive astrocytes 
within active lesions [125]. 
7.1.3. Onset of an Immune Response against These Elements 
Growing evidence suggests that HERV-W/MSRV Env may act as super-Ag that triggers an 
abnormal innate immune response independently of a specific recognition pathway. This immune 
activation could lead to the overproduction of cytokines, which are known to play a major role in MS 
inflammatory demyelinating process. MSRV Env induced in both healthy donors and MS patients 
the in vitro polyclonal activation of Vβ16 T-lymphocytes [126] and the subsequent increase of 
multiple pro-inflammatory cytokines [126,127]. These HERV-W/MSRV Env pro-inflammatory 
properties have been attributed to the protein’s ability to trigger the Toll-Like Receptor 4 (TLR4) 
[126,128,129], leading to the overexpression of the same proinflammatory cytokines involved in MS, 
such as interleukins 1 and 6 (IL-1, IL-6) and Tumor Necrosis Factor α (TNF-α), and inducing 
lymphocyte Th-1 polarization [127,128,130]. Moreover, HERV-W Env interaction with TLR4 and the 
consequent upregulation of proinflammatory factors, in particular inducible nitric oxide synthase, 
led to the formation of nitrotyrosine groups, which directly affected myelin expression and 
remyelination by blocking oligodendrocyte precursor differentiation [131]. In support of these 
findings, HERV-W Env neutralization by monoclonal Ab GNbAC1 reduced such stress reactions  
and rescuing myelin expression [132], and MSRV Env was recently confirmed to be a potent agonist 
of human TLR4 in vitro and in vivo [133].  
However, some reports assessed the development of a specific humoral response against HERV-
W/MSRV in MS patients, and found weaker support for its role in MS pathogenesis. Ruprecht et al. 
reported the presence of Syncytin-1 Abs in only 1 of 50 MS patients and in none in 59 controls, 
whereas MSRV Gag or Env Abs were not detected [112]. In a follow up study in MS patients that 
monitored Abs titers against HERV Env proteins, a decrease in anti-HERV-W Env reactivity as a 
consequence of interferon (IFN)-β therapy was reported but the decrease was not statistically 
significant [134], as previously observed for circulating Env RNA [135]. Finally, a study assessing the 
humoral response against selected HERV-W Env peptides showed that two peptides were strongly 
recognized by MS patients IgG as compared to controls, and a decrease in recognition after six 
months of IFN-β therapy was also reported [136]. 
7.1.4. Use of Some Animal Models of MS 
The potential link between HERV-W/MSRV immunopathogenic properties and MS has been 
investigated through mice models, which generally supported the active involvement of these 
elements in disease development. Intraperitoneal injection of MSRV virions in immunodeficient mice 
transplanted with human lymphocytes led to the onset of acute neurological symptoms, causing 
death by massive brain hemorrhage [137]. Further analysis confirmed the presence of circulating 
MSRV RNA and splenic overexpression of proinflammatory cytokines [137]. In another study, 
Syncytin-1 induced neuroinflammation, neurobehavioral abnormalities and oligodendrocyte and 
myelin injury principally evoked by redox reactant–mediated cellular brain damage [118,138]. 
Always in mice, MSRV-Env was able to activate the TLR4- and CD14-mediated release of 
proinflammatory cytokines and, when associated to the myelin oligodendrocyte glycoprotein (MOG) 
Ag, induced a specific T cells IFN-C production. Such combined innate and acquired responses 
promoted the development of experimental allergic encephalomyelitis, and was proposed as a 
suitable MS animal model [139]. 
In addition to the high number of studies that all assessed the whole group general expression 
in MS, a limited number of studies were dedicated to the investigation of individual transcribed 
HERV-W loci. The HERV-W processed pseudogene in locus Xq22.3 (ERVWE2) was among the most 
highly investigated due to the presence of an almost complete env ORF, interrupted only by a 
premature stop at codon 39. Noteworthy is that this L1-retrotransposed HERV-W element is 
transcribed in human PBMCs [13,140,141], producing ex vivo an N-terminally truncated Env protein 
(N-Trenv) [142]. In addition, the evidence that a monoclonal Ab previously used to detect HERV-W 
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Env in MS lesions (13H5A5) [123] was able to bind N-Trenv, but not Syncytin-1, allowed speculation 
that this and other expressed defective proteins may exert some effects in vivo [142]. Also, the 
ERVWE2 locus in chromosome X has been proposed as the hypothetical genomic origin of MSRV 
Env proteins [108,110] and investigated for its potential role in MS and its higher incidence in women. 
However, analysis of ERVWE2 DNA sequences in MS patients and healthy individuals PBMC 
revealed that all harbored the stop codon at site 39, and assessed whether genetic polymorphisms 
could possibly allow the production of a full-length protein in vivo [143]. The authors also identified 
5 ERVWE2 DNA regions similar to the MOG Ig-like domain that, together with other co-factors, 
could trigger the immune cross-reaction against myelin in MS [143]. García-Montojo et al. genotyped 
the ERVWE2 insertion in a wide group of individuals, and reported a significant association with 
female MS susceptibility and polymorphisms rs6622139 and rs1290413, which are more frequent in 
controls than MS affected women [144]. A similar analysis was performed for an HERV-W insertion 
in chromosome 20, but the two identified polymorphisms were not significantly linked to MS 
susceptibility based on case–control studies [145]. Other work addressed HERV-W loci expression in 
MS. Laufer at al. tried to clarify the origin of the HERV-W/MSRV env sequences detected in MS 
samples by evaluating expression from single HERV-W loci. Interestingly, expressed HERV 
sequences was shown to be often complicated by in vitro recombination between HERV transcripts, 
probably caused by RT template switches and/or PCR-mediated recombination [13,141]. In 
particular, the authors proposed that some previously published MSRV env sequences, as well as a 
high number of HERV-W env cDNA clones, had actually arisen from the recombination of different 
HERV-W env transcripts, detecting up to four recombination events involving up to five HERV-W 
loci for the same sequence. It was also shown that the primers commonly used for HERV-W 
expression studies were similar enough to anneal with multiple HERV-W loci, underlining the 
importance of precisely assessing the transcripts genomic origin when studying HERV RNA 
expression [83,141]. Of note, similar individual HERV-W env loci expression levels were found in 
PBMCs from MS patients and healthy controls [141], further supporting the low specificity of RNA 
transcripts for MS disease. Another comprehensive analysis of HERV-W loci brain transcription was 
performed by high-throughput sequencing of env-specific RT-PCR products, identifying >100 HERV-
W loci transcribed at very similar levels in MS patients and healthy individuals [113]. Interestingly, 
while the deregulated expression of HERV-W env in MS brain lesions was refuted, the authors 
reported an inter-individual variability in HERV-W transcript levels, and a residual promoter activity 
for many HERV-W LTRs, even if incomplete [113]. A third study analyzing age- and disease-
dependent HERV-W env RNA diversity showed that HERV-W env transcripts originated from 
multiple loci in primary human neurons, while astrocytes and microglia showed lower diversity in 
HERV-W transcript chromosomal origin [146]. Similarly, while multiple loci encoding HERV-W env 
RNA sequences were detected in both fetal and adult healthy brains, transcripts cloned from 
neurologic patients mostly mapped to Syncytin-1 locus (7q21.2), and their abundance was highly 
correlated with pro-inflammatory gene expression in diseased brains [146]. This could indicate a 
wide and complex scenario, poorly clarified by the mere upregulation of general HERV-W group 
expression. 
Taken together, HERV-W/MSRV expression analyses in MS patients do not definitively confirm 
a specific association of these retroviral elements to MS etiology, but strongly suggest a possible role 
of group expression, especially at the protein level, in disease immunopathogenesis. Variable HERV-
W/MSRV expression found in both MS patients and healthy individuals could probably constitute a 
normal physiological phenomenon, possibly with higher prevalence in MS due to an altered 
epigenetic and immunological environment [94,147]. This hypothesis opens the possibility of a co-
contributing role or predisposing factors that will require additional studies on the HERV-W/MSRV 
brain proteomic profile in different ethnic populations [147]. In fact, considering the non-specific 
super-Ag activity of HERV-W/MSRV Env showed neuropathogenic effects coincident with the major 
hallmarks of MS inflammation [125], the HERV-W group could participate in a complex 
inflammatory interplay with other not fully understood factors, including genetic predisposition and 
exogenous infections [97,148]. It is noteworthy that a therapeutic treatment targeting HERV-
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W/MSRV has been proposed as a possible innovative approach for MS using the GNbAC1 
monoclonal Ab developed to selectively recognize MSRV Env. It showed neutralizing effects in vitro 
and in MS mouse models and is currently in phase II clinical development [149,150]. 
7.2. Other Autoimmune Diseases 
Besides MS, a few studies investigated HERV-W group expression in other disorders with 
poorly understood etiology, in which autoimmunity mechanisms play a major pathogenic role, such 
as rheumatoid arthritis (RA), osteoarthritis (OA), chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP), psoriasis and lichen planus (LP). In all these disorders, no evidence 
of an etiological link between HERV-W expression and pathogenesis has been reached yet, mostly 
due to the poor sample representation and failure to assign the observed transcripts to individual 
HERV-W loci. 
RA is characterized by the progressive destruction of articular components and leads to severe 
disability. A common sign of the RA autoimmune response is the presence of a cellular infiltrate of 
neutrophils, lymphocytes, and macrophages in the synovial tissue, accompanied by the increased 
production of metalloproteinases contributing to extracellular matrix erosion [151]. Based on 
preliminary results reporting HERV-W/MSRV RNA in the 50% of RA patient plasma samples, 
Gaudin et al. determined if particle-associated HERV-W/MSRV RNA were present in patient samples 
[151]. The results showed that neither the patients nor the controls had HERV-W/MSRV RNA in 
plasma, while such RNA was detected in the synovial fluid samples of two out of nine RA patients 
and one control, suggesting its lack of specificity with respect to RA etiology [151].  
OA is another common form of arthritis characterized by the progressive destruction of articular 
cartilage, in which many factors, including viral infections, seem to play a role [152]. Bendiksen et al. 
analyzed cartilage and chondrocytes from advanced OA as compared to early/non-OA individuals. 
While all samples were negative for a number of exogenous infections, a HERV-W env gene was 
commonly expressed in advanced OA patient cartilage (88% of patients) while expression was 
detected in a lower proportion of controls (0–38%) [152]. The authors also reported the abundant 
expression of Env proteins in OA-derived chondrocytes, and the occurrence of viral budding and 
virus-like particles. However, the particles were neither isolated nor characterized [152].  
Another pathology tentatively linked to HERV-W/MSRV is CIDP, a rare immune disease of the 
peripheral nervous system characterized by inflammatory and demyelinating lesions in nerve roots 
[153]. Driven by the presence of MSRV-Env in a small number of CIDP patients (5 out of 8) [120], 
Faucard et al. confirmed an upregulation of MSRV env and/or pol mRNAs in 50–65% of CIDP 
patients PBMC [153]. The authors also reported the presence of MSRV Env protein in 5 out of 7 CIDP 
patients nerve lesions and dominant expression in Schwan cells [153]. Moreover, Schwan cell cultures 
exposed to MSRV-Env displayed a potent induction of IL-6 and CXCL10 chemokines, which could 
be significantly inhibited by GNbAC1 MSRV-Env mAb [153].  
Finally, HERV-W/MSRV expression may contribute to some skin diseases with unclear etiology. 
Psoriasis is a chronic disease characterized by epidermal proliferation and abnormal keratinocytes 
differentiation and shows similarities to systemic immunological disorders closely related to 
autoimmunity [154]. Considering that HERV expression has been reported in human skin, being 
either activated or repressed by UV irradiation [155,156], Molès et al. assessed HERV expression in 
psoriatic lesions. Their work detected various pol amplicons comprising HERV-W sequences in both 
psoriatic and control skin samples [154]. Another pathology taken into account was LP, a chronic skin 
inflammatory disease characterized by lichenoid papules and possibly involving also microbial 
agents in its unclear etiology [157]. de Sousa Nogueira et al. observed a downregulation of some 
HERV groups, including HERV-W env, in skin biopsies of LP patients, with a concomitant activation 
of antiviral restriction genes APOBEC3G, MxA, and IFN-inducible genes that may be involved in 
immune control of HERV transcription [157]. 
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8. HERV-W Expression in Neurological and Neuropsychiatric Disorders 
HERV-W neuropathogenic effects have also been investigated in a number of neurological and 
neuropsychiatric diseases with poorly understood etiology, such as Motor Neuron Disease (MND), 
sporadic Creutzfeldt–Jakob disease (sCJD), autistic spectrum disorder (ASD), attention deficit 
hyperactivity disorder (ADHD), and schizophrenia. In general, the available information does not 
yet support a direct role of HERV-W group in any neurological or neuropsychiatric diseases. In fact, 
a proportion of HERV-W-negative patients is reported in the majority of the studies, while a 
significant upregulation of HERV-W expression was shown in a subset of cases, strongly suggesting 
the presence of other major factors contributing to a complex and poorly understood etiology. It is 
also worth noting that many of these pathologies could be concomitant with behavioral variables, 
such as drug and alcohol abuse [158], which could be confounding if they are able to influence HERV 
brain expression [159].  
MND is a heterogeneous group of neurologic disorders characterized by the progressive 
degeneration of motor neurons. Elevated levels of HERV-W env transcripts were observed in biopsies 
from MND patients limbs as compared to control tissues from the same individual and from healthy 
donors [160]. The authors also detected a parallel upregulation of the SOD1 (oxidative stress-
responsive) gene, a marker for oxidative stress, suggesting that its activation could be due to the 
primary loss of motor neurons instead of being a direct consequence of HERV-W Env neurotoxic 
effects [160].  
sCJD is a rare form of prion disease, causing fatal neurodegeneration and having as key event 
the conformational change of cellular prion protein to an abnormal protease-resistant isoform. Joang 
et al. examined the expression of 10 HERV groups in sCJD patients CSFs, detecting transcripts of all 
analyzed groups and reporting the highest incidence for HERV-W pol (82.5% positivity), with a 
significant increase with respect to controls [161]. Based on subsequent subcloning analysis, all 
observed transcripts showed non-identical nucleotide sequence, and none had specificity for sCJD 
[161].  
ASD and ADHD are two neurodevelopmental diseases caused by complex interactions with not 
fully clarified genetic and environmental factors. ASD patients PBMC showed higher positivity for 
HERV-H and HERV-W mRNAs as compared to controls [162]. Subsequent quantification showed 
that HERV-H and HERV-W were, respectively, more and less abundantly expressed in ADS patients 
[162]. Similarly, the HERV-H transcript level in ADHD patients PBMC was significantly higher, while 
no differences were found in HERV-W expression [163].  
Among neuropsychiatric disorders, the field of greatest interest for HERV-W involvement is 
schizophrenia. The first findings were provided by Deb-Rinker et al. in monozygotic twins discordant 
for schizophrenia, presenting one sequence (schizophrenia associated retrovirus, SZRV-1, AF135487) 
similar to both a MSRV (AF009668) and a HERV-9 (S77575) sequences expressed in placenta [164]. 
Karlsson et al. then detected HERV-W/MSRV pol sequences in the cell-free CSF from 29% acute onset 
schizophrenia patients and 5% individuals in later stages of the disease, but not in patients with non-
inflammatory neurological diseases and healthy controls [165]. Similarly, HERV-W/MSRV 
expression was up-regulated in the brain frontal cortex regions of schizophrenia patients when 
compared with control tissues from healthy individuals [165]. In subsequent studies, the same 
authors reported the presence of HERV-W RNA in the plasma of a subgroup (9 out of 54) of recent-
onset schizophrenia patients, 5 of which harbored HERV-W/MSRV sequences in CSF [166]. They 
detected an elevated level of HERV-W gag (but not env) transcripts in PBMC of patients with 
schizophrenia-related psychosis, and reported an upregulation of HERV-W sequences from locus 
11q13.5 [167]. HERV-W env plasmatic mRNA was found in 36% of recent-onset schizophrenia 
patients and in none of the 106 controls, and also RT activity was significantly increased in patient 
sera [168]. At the protein level, HERV-W Env hyperexpression in U251 human glioma cells triggered 
the production of the dopamine receptor D3 and brain-derived neurotrophic factor (BDNF), both 
associated with schizophrenia, and increased the phosphorylation of CREB protein, which is 
necessary for BDNF expression [168] and confirmed in human neuroblastoma cells [79]. Moreover, 
recent findings also suggested that phosphorylation of Glycogen Synthase Kinase 3β might be 
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involved in HERV-W Env-mediated BDNF induction [169]. A study detecting HERV-W Ags in 
patients reported positive serum antigenemia for Gag and Env in ~50% of schizophrenic patients and 
in 3–4% of blood donors [170]. Of note, a full-length HERV-W LTR was found in the regulatory region 
of GABBR1 (GABA receptor B1) gene, which is downregulated in schizophrenic patients [171]. 
However, the roles of this LTR and GABBR1 in schizophrenia remain to be clarified. 
In contrast to the studies reported above, which showed an increased HERV-W expression in 
Schizophrenia [166–168], a number of investigations reported no specific correlation between the 
HERV-W transcription and development of neurological diseases [158,172,173]. The comprehensive 
microarray-based analysis of 20 HERV group’s transcriptional activity in 215 brain samples from 
schizophrenia or bipolar disorders (BD) patients and matched controls failed to show relevant links 
between HERV brain expression and schizophrenia, suggesting that it could be more likely that 
HERV transcriptional activity is influenced by the individual genetic background and the presence 
of immune cell infiltrates and/or medical treatments [172]. Interestingly, the different brain areas of 
each individual showed a common pattern of HERV expression, where the HERV-W env gene was 
transcriptionally active but did not show significant differences between healthy controls and 
schizophrenic patients [172]. Weis et al. observed that HERV-W Gag proteins were present in human 
brain anterior cingulate cortex and hippocampus, mostly associated with neurons and astrocytes, and 
showed significantly reduced expression in schizophrenia, major depression, and BD patients as 
compared to controls [158]. HERV-W env transcription was increased in schizophrenia and BD 
patient PBMCs, but the corresponding DNA copy number was paradoxically lower in patients than 
in healthy controls. Moreover, differences in HERV-W env amplicon nucleotide sequences and their 
relative frequencies were observed in comparisons of patients to controls and in comparisons among 
Schizophrenia and BD patients to MS patients [173]. The authors hypothesized that when HERV-W 
genes are hypomethylated during development, environmental stimuli (such as exogenous 
infections) could prompt lineage-specific HERV-W genomic modifications and determine variable 
patterns responding differently to subsequent environmental triggers, leading to diverse clinical 
manifestations [173].  
9. HERV-W Expression in the Presence of Exogenous Infections 
HERVs have also been proposed to influence exogenous viral infections, and such a role could 
be either beneficial or harmful. HERV antisense transcripts have been hypothesized as a plausible 
defense against exogenous infections, in which complementarity between homologous retroviral 
RNA sequences could form dsRNA and detected as a PAMP by the innate immunity PRRs [89,174]. 
Another possible HERV-mediated antiviral effect could be the partial resistance to infection, evoked 
by receptor interference and blocking by HERV proteins [175,176]. However, exogenous viruses and 
expressed HERVs may also generate cooperative effects, stimulating each other’s transcription or 
leading to the complementation of defective elements. Clearly, some of these interactions require a 
certain degree of sequence and structural homology, and are most likely to happen between HERVs 
and exogenous retroviruses. 
9.1. Retroviral Infections 
Humans are currently threatened by two exogenous retroviruses: Human Immunodeficiency 
Virus (HIV, Lentiviridae) and Human T-cell Lymphotropic Virus (HTLV, Deltaretroviridae). HERV-W 
Env glycoprotein was shown to functionally complement an env-defective HIV-1 strain, generating 
HERV-W-pseudotyped particles infectious for CD4-negative cells, and therefore, possibly expanding 
HIV-1 tropism [177]. HERV-W elements were upregulated in three persistently HIV-1 infected cell 
lines, but not in infected cells [178]. Of note, reversal of HIV-1 latency by treatment with histone 
deacetylase inhibitors caused no substantial increases of HERV-W env gene transcription [179]. 
Significant HERV-W RNA hyperexpression was detected in the brains of AIDS patients suffering 
from dementia [114]. However, this variation in expression is probably a consequence of increased 
immune activity linked to monocyte differentiation and macrophage activation, and had no active 
role in AIDS neuropathy. HIV Tat transactivator protein increased MSRV env mRNAs and HERV-W 
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Env protein expression in astrocytes and differentiated macrophages but reduced expression in 
monocytes [180]. Similarly, HTLV-I Tax homolog of Tat also activates transcription from HERV-W 
LTRs by interacting with CREB along with other transcription factors [181]. T cell cross-reactivity 
between HERV and HIV epitopes was tested in vitro, giving negative results [182]. 
9.2. Herpesviral Infections 
The possible interplay between Herpesviruses infection and HERV-W expression has been 
widely analyzed, especially in the context of MS and autoimmunity, and the ability of various 
Herpesviruses to influence HERV-W transcription [85–87]. HERV-W/MSRV expression was 
enhanced by Herpes Simplex Virus 1 (HSV-1) superinfection in MS patients cells [41,96,183]. More 
specifically, Lafon et al. showed that HERV-W Env protein expression in neuroblastoma cell lines can 
be reactivated by HSV-1, probably through its infected cell polypeptide 0 and 4 (ICP0 and ICP4, 
respectively) early proteins [96]. HERV-W Gag and Env proteins were also induced by HSV-1 in 
neuronal and brain endothelial cells in vitro, and expression was also compatible with an ICP0-
mediated activation [184]. Additional evidence has been reported in HeLa cells, in which HSV-1 IE1 
protein stimulated LTR-driven transcription of HERV-W elements, probably through the modulation 
of the Oct-1 transcription factor [185]. The authors proposed that IE1 activation could also involve 
HERV-W solitary LTRs, potentially promoting possible nearby genes [185]. 
Besides HSV-1, other Herpesviruses have been analyzed for their ability to activate HERV-W in 
MS. A hypothetical ERVWE1 Env peptide (29 aa) harbored an epitope predicted to be presented by 
different HLA class I molecules and possibly acted as a target for effector T-cells in MS. Interestingly, 
this epitope was partially homologous with all the pathogens against with elevated Abs titers in MS 
patients, including HSV-1, HHV-6, VZV (Varicella Zoster Virus), EBV (Epstein Barr Virus), and 
measles virus [186]. Hence, it was claimed that the effector T cell recognizing this putative epitope 
would most readily cooperate with regulatory T cells to support an immune response, leading either 
to a prompt resolution of the infection or to tissue damage by autoimmune processes [99,186]. 
Regarding EBV, the exposure to the virus or to its major Env glycoprotein (gp350) triggered HERV-
W/MSRV expression in PBMCs from MS patients and MSRV positive healthy controls, as well as in 
cultured U87-MG astrocytes, with an activation pathway possibly involving NF-kB [187]. The 
infection of a number of cancer and non-cancer cell lines with CMV induced RT activity in all cells, 
and upregulated various HERVs, including HERV-W, in CMV-infected neural tumor stem cells after 
UV irradiation [188]. Other evidence of a helper role in HERV-W activation came from kidney 
transplant recipients with high CMV load, who displayed significantly higher HERV-W pol 
expression than patients with moderate/undetectable CMV load or healthy subjects [189].  
9.3. Other Exogenous Infections 
Although retroviral and herpesviral infections have been most intensively studied for their 
effects on HERV-W expression, influenza virus, spleen necrosis virus (SNV) and porcine endogenous 
retrovirus (PERV) infections have also been implicated in modulating HERV-W. 
Nellåker et al. described specific expression patterns of HERV-W gag and env genes (even if 
encoded by sequences with truncated/no LTRs) in different cell-lines, and observing subsets of 
elements being transactivated by influenza virus active replication [140]. Similar variations were also 
observed as a consequence of serum deprivation, suggesting that the cellular stress itself could 
contribute to HERV-W modulation [140]. Subsequent analysis showed that influenza virus infection 
induced spliced ERVWE1 transcripts able to encode Syncytin-1 in extra-placental cells by GCM1 
overexpression [190], and downregulated the level of repressive histone mark H3K9me3 [191]. 
The HERV-W Env glycoprotein induced cellular resistance to SNV, whose infectivity was 
reduced by 1000-10,000-fold in D-17 cells expressing HERV-W Env [192]. 
Finally, in the field of xenotransplantation, the expression level of HERV-W genes differed in 
PERV-infected HEK-293 cells in comparison to uninfected cultures [193]. 
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10. The HERV-W Transcriptional Landscape in the Context of Human Physiopathology: Current 
Needs and Future Perspectives 
As described in the previous sections, no definitive link between HERV-W expression and 
disease onset and progression has been found. The great majority of the studies, in fact, have been 
based on the detection and the eventual quantification of expression from the entire HERV group. 
The analysis of bulk HERV expression cannot reveal the contribution of specific HERV-W loci to 
physiological or pathological disease states. Furthermore, most of the studies have been based on not 
fully standardized methodologies performed on differently representative samples. Thus, although 
a great amount of data has been generated, they are frequently discordant and difficult to compare 
with each other. The main biases that affected, in our opinion, a great number of studies aimed at 
analyzing the HERV-W group expression are summarized in Table S2, along with their inconclusive 
nature and suggestions for improvement.  
The currently available information strongly suggests that the HERV-W group is commonly 
transcribed in human cells, and that this happens in both healthy and pathological conditions. 
Collective expression greatly varies between tissues and reflects individual genetic backgrounds. In 
particular, the presence of HERV-W RNA and Ags in human tissues and cells seems to be a 
physiological phenomenon. HERV-W expression is detected in (a subset of) healthy individuals and 
possibly increases under pathological conditions, without necessarily representing an etiological 
factor. The direct pathogenic effects of HERV-W RNA and proteins have not been confirmed and still 
lack a molecular mode of action in vivo. In contrast, the effects that these HERV-W products could 
trigger in their interplay with the host—including immune stimulation, insertional mutagenesis (also 
through de novo retrotransposition events) and deregulatory functions—are more likely to 
contribute to human pathogenesis, and also influence some animal models of human disease. Even 
in this case, however, the identification and characterization of the specific HERV-W sequences and 
the exact molecular mechanisms involved remains a major goal and necessary for the exploitation of 
HERV-W candidates for therapeutic purposes. 
Defining the expression patterns of single HERV-W loci through a dedicated microarray or 
RNA-seq analyses will be essential to provide additional insights into the quantitative changes 
originating from specific HERV-W sequences and to identify single members possibly linked to 
human pathogenesis. Indeed, this promising field deserves a deeper investigation aimed, first of all, 
at characterizing all the possible mechanisms involving HERV-W presence and expression in both 
physiological and pathological conditions. The latter also includes the possibility that an altered 
epigenetic environment could prompt de novo mobilization of HERV-W transcripts by active L1 
elements. This ongoing process would generate additional HERV-W processed pseudogenes when 
compared with the ones recently mapped in the human genome reference sequence [21]. 
The current lack of knowledge of the individual HERV-W loci transcriptional status is in large 
part due to the previous incomplete characterization of the HERV-W genomic landscape. Much of 
the current experimental designs have focused on a few HERV-W sequences, above all Syncytin-1 
and MSRV clones (Table S2). This has prevented until now (i) the univocal assignment of the HERV-
W expressed sequences to the locus of origin; (ii) the characterization of the single HERV-W 
sequences differential expression in the diverse physiological tissues, essential to assess their effective 
dysregulation in diseased environments; (iii) the evaluation of the full-length HERV-W sequence 
transcription, coding capacity and regulatory elements; (iv) the characterization of the single HERV-
W sequences epigenetic status in both physiological and pathological contexts, and (v) the study of 
the HERV-W sequences genomic context of insertion, identification of nearby host genes that can 
potentially influence (or be influenced by) HERV-W elements even in the absence of a detectable 
expressed product (Table S2). 
We also outline future research investigating HERV-W’s contribution to human 
physiopathology, including dedicated genome-wide high-throughput studies using stringent 
primers and probes that are able to distinguish the uniqueness of single HERV-W elements 
conforming to standard conditions. Developing these reagents will help properly define the specific 
contribution of the different retroelements to the human transcriptome [95]. Importantly, the 
Viruses 2016, 8, 162 25 of 35 
 
physiological consequences of individual HERV-W loci expression must be evaluated a priori, in 
order to have a reliable “basal” level to compare with the same, diseased, tissue [86]. Such specific 
quantitative analyses must then be performed on a statistically significant population, possibly 
including paired samples of both healthy tissues and pathological lesions from the same individual. 
Moreover, these investigations also take into account the influence of the HERV-W loci genomic 
context of integration, and to analyze the molecular diversity of single insertions within the human 
population. HERV-W polymorphisms are necessary to understand due to the possibility that 
different HERV-W allelic variants may exert specific effects on the pathogenesis phenotype, 
progression and therapeutic response, depending on the host genetic background [95]. Considering 
that ~80–100 copies of L1 are active in the human genome [36,39,194], the eventual L1-mediated 
retrotransposition of HERV-W sequences should also be considered, especially in those pathological 
environments associated with an altered epigenetic control, where the hypomethylation of both L1 
and HERV-W sequences have been reported [74]. Finally, since structurally-incomplete LTRs could 
be still able to drive the transcription of HERV-W proviruses, processed pseudogenes or nearby host 
genes, the methylation levels of truncated and solitary LTRs should also be evaluated. Indeed, besides 
detecting HERV-W group overall expression, the identification of the specific encoding locus appears 
to be mandatory to establish any definitive associations between human diseases and specific 
retroelements, and also to properly understand the molecular nature of emergent forms that have 
arisen through recombination events involving different HERV-W loci [95], especially in those 
contexts where the epigenetics alteration could liberate HERVs expression. Similarly, the molecular 
determinants responsible for specific HERV-W loci upregulation as well as their role either as a cause 
or a consequence of disease must also be clarified in detail [97]. Together, these approaches will 
finally provide well-characterized mechanisms of HERV-mediated pathogenesis. 
In conclusion, it is certainly possible and perhaps likely that specific HERV-W sequences may 
play a role in human pathogenesis, without necessarily being the only etiological determinant of 
disease. Indeed, in the field of autoimmunity, one or more HERV-W insertions (or even specific allelic 
variants) and/or their expressed products may be involved in a complex inflammatory and immune 
interplay with other unknown or not fully understood co-factors. The latter may include individual 
predispositions, depending on the host genetic background, as well as extrinsic factors such as stress, 
environmental stimuli or exogenous infections. All these complex relationships must be considered, 
especially in the field of multifactorial disorders with poorly clarified etiology. In light of this, the 
identification and characterization of the precise HERV-W loci showing a differential transcription 
pattern and/or L1-mediated HERV-W de novo mobilization in a specific pathological context appear 
to be mandatory to definitively demonstrate a cause–effect connection to any disease etiology, and to 
subsequently identify single HERV-W sequences exploitable as novel therapeutic targets. The latter 
could be suitable for various, innovative approaches, from the employment of retroviral inhibitors to 
the administration of passive as well as active immunotherapy directed against specific HERV 
products, possibly in association with the treatment with DNA-demethylating agents. However, 
even in the absence of an etiological contribution, the identification of specific HERV-W sequences 
selectively expressed in a given pathological context could provide novel and reliable sequence-based 
biomarkers of disease. Also, disease-associated Ags suitable for directing immunotherapeutic 
approaches to the precise site of pathogenesis could be developed as protein biomarkers. All these 
HERV-based therapeutic applications could certainly constitute an innovative treatment for many 
human diseases. 
Supplementary Materials: The following are available online at www.mdpi.com/1999-4915/9/5/162/s1. Table S1: 
Syncytin-1 expression in pathological placentas, Table S2: Major biases and current needs for HERV-W 
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